Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 4, 2009, Pages 437-444

  Krishna, Gopal ^a   Moton, A ^b   Ma, L ^b   Martinho, M ^b   Seiberling, M ^b   McLeod, J ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

Antiretroviral agents; Azole antifungals; Drug interactions; Posaconazole

Indexed keywords

ATAZANAVIR; BILIRUBIN; EFAVIRENZ; POSACONAZOLE; RITONAVIR;

ABDOMINAL PAIN; ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRY LIPS; EYE JAUNDICE; FEMALE; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN EXPERIMENT; LIP DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BENZOXAZINES; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; TRIAZOLES;

EID: 68049142170     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181acb51b     Document Type: Article

References (34)

1. Benson CA, Kaplan JE, Masur H, et al. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents. Recommendations From CDC, The National Institutes of Health, and The HIV Medicine Association/Infectious Diseases Society of America. Atlanta, GA: Centers for Disease Control and Prevention; 2007.
2. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000;38:111-180. (Pubitemid 30122116)
3. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf. 1998;18:83-97. (Pubitemid 28080742)
4. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006;50:2009-2015.
5. Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther. 2005;3:467-487.
6. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-347. (Pubitemid 46148776)
7. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359. (Pubitemid 46148777)
8. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42:1398-1403.
9. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12. (Pubitemid 44968977)
10. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50:658-666. (Pubitemid 43190980)
11. van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61-e65.
12. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21:645-653. (Pubitemid 38447146)
13. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004;32:267-271. (Pubitemid 38176945)
14. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother. 2004;48:3543-3551. (Pubitemid 39129357)
15. BMS Virology. Reyataz™ (atazanavir sulfate) capsules [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2003.
16. Norvir® (ritonavir capsules) soft gelatin; (ritonavir oral solution) [package insert]. North Chicago, IL: Abbott Laboratories; 2006.
17. Sustiva® (efavirenz) capsules and tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2007.
18. Hariparsad N, Sane R, Desai PB. Induction of PXR target genes by non-nucleoside reverse transcriptase inhibitor, efavirenz, and protease inhibitors [PIs] ritonavir and nelfinavir. Presented at: American Association of Pharmaceutical Scientists Annual Meeting, November 6-10, 2005; Nashville, TN.
19. Mossdorf E, Kummer O, Kraehenbueh S, et al. Efavirenz induction of the UGT-1A1 reduces atazanavir induced hyperbilirubinemia. Presented at: 8th International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, United Kingdom.
20. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192:1381-1386. (Pubitemid 41401151)
21. Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal. 2007;43:228-236. (Pubitemid 44856187)
22. Kakuda TN, Struble KA, Piscitelli SC. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health Syst Pharm. 1998;55:233-254. (Pubitemid 28109897)
23. Cato A III, Cao G, Hsu A, et al. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab Dispos. 1997;25:1104-1106. (Pubitemid 27396501)
24. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother. 2007;51:3617-3626. (Pubitemid 47519352)
25. VFEND® (voriconazole) [package insert]. New York, NY: Pfizer Inc; 2006.
26. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin. 2007;23:1415-1422. (Pubitemid 46998449)
27. Krishna G, Parsons A, Kantesaria B, et al. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin. 2007;23:545-552. (Pubitemid 46456902)
28. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology. 2004;63:S3-S8.
29. Reinach B, de Sousa G, Dostert P, et al. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact. 1999;121:37-48. (Pubitemid 29240668)
30. Oesch F, Arand M, Benedetti MS, et al. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother. 1996;37:1111-1119. (Pubitemid 26258057)
31. Sriwiriyajan S, Mahatthanatrakul W, Ridtitid W, et al. Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. Eur J Clin Pharmacol. 2007;63:479-483. (Pubitemid 46569926)
32. Koo HL, Hamill RJ, Andrade RA. Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Clin Infect Dis. 2007;45:e77-e79.
33. Moton A, Ma L, Krishna G, et al. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin. 2009;25:701-707.
34. Smith DE, Jeganathan S, Ray J. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials. 2006;7:34-38.